FDA Grants Accelerated Approval to Jemperli for Rectal Cancer Subtype, Potentially Avoiding Surgery

The FDA has granted accelerated approval to Jemperli (dostarlimab-gxly), an immunotherapy, for adults with previously untreated stage II or III rectal cancer that is mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H). This approval, based on interim trial results, may allow some patients to avoid surgery, radiation, and chemotherapy.